Advertisement

CoreValve Gains New Indication for High-Risk Patients — Physician’s First Watch

Medical News |
June 16, 2014

CoreValve Gains New Indication for High-Risk Patients

By Larry Husten

Edited by Susan Sadoughi, MD, and Jaye Elizabeth Hefner, MD

Medtronic's CoreValve system gained a second indication from the FDA for use in patients with severe aortic stenosis who are at high risk for surgery. The transcatheter aortic valve replacement (TAVR) system was initially approved earlier this year for use in patients who were too ill or frail for traditional open heart surgery.

The new approval is based on results from the U.S. CoreValve High-Risk Study published in the New England Journal of Medicine. In the trial, 795 patients with severe aortic stenosis who were at high risk for surgery were randomized to surgical aortic valve replacement (SAVR) or CoreValve. At 1 year, the rate of death was 14.2% in the TAVR group versus 19.1% in the SAVR group, a difference that was highly significant for noninferiority and even reached significance for superiority.

Adapted from CardioExchange.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement